Assessment of Serum Levels of Janus Kinase 1 and 2 in Patients With Cholinergic Urticaria
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- serum levels of janus kinase 1
研究概览
简要总结
Cholinergic Urticaria (CholU) is as a subtype of CIndU caused by an increase in the core body temperature, such as to activate the sweating reflex. It can occur in response to physical exercise, hot bathing and/or emotional stress. Clinically it appears as pinpointing and highly pruritic wheals with surrounding erythema, CholU can be accompanied by severe symptoms such as angioedema, respiratory symptoms or anaphylaxi CholU is frequently associated with atopic dermatitis (AD) The JAK-STAT is a mast cell (MC) signaling pathway activated downstream of IgE and IL-3 with important roles in MC homeostasis via regulation of proliferation, survival, and release of mediators. JAK-STAT activation is associated with polarization toward Th2, B cell isotype switching to IgE production, and IgE-dependent degranulation and cytokine release .
Because both IL-4 and IL-13 use the IL-4Rα as a receptor component, these cytokines activate any common signaling pathways. Both of these cytokines use Janus kinases (JAKs) to initiate signaling and activate signal transducer and activator of transcription-6 (STAT6), which is a transcription factor required for many of their biologic functions.
The non-receptor protein tyrosine kinases JAK1 and JAK3 associate with the IL-4Rα and γC, respectively. The binding of IL-4 to its receptor induces the transphosphorylation of JAK1 and JAK3, an event that activates these kinases and thereby initiates the early events of signal transduction .
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 55 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The study will include 45 adult patients complaining of CholU as well as 45 healthy controls.
排除标准
- •Patients with one or more of the following criteria will be excluded:
- •Pregnancy and lactation.
- •Patients with systemic diseases especially those with autoimmune diseases and infections.
- •Patients with skin diseases.
- •Patients on medications such as: antibiotics, non-steroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, anticonvulsants, penicillin, combined oral contraceptives.
- •Patient refusal
结局指标
主要结局
serum levels of janus kinase 1
时间窗: 1 year
assessment of serum levels of janus kinase 1
次要结局
- serum levels of janus kinase 2(1 year)
研究者
Marwa Elsayed Mohamed
Resident-Dermatology department-sohag hospital university
Sohag University
